Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Shephard/Phillips TMAU webinar 09/12
Similar to Shephard/Phillips TMAU webinar 09/12 (20)
Recently uploaded
Recently uploaded (20)
Shephard/Phillips TMAU webinar 09/12
- 1. FMO3 bugs, genes and drugs Elizabeth Shephard and Ian Phillips webinar, September 2012
- 2. FMO3 Flavin-containing monooxygenase 3 • FMO3 – mutations can cause Trimethylaminuria, TMAU • FMO3 – is a drug metabolising enzyme
- 3. BUGS Gut microbiome • Human body made up of ~1013 cells • Our intestines contain ~1014 bacterial cells • Gut microbiome is our second genome • Now recognised as a key factor in health and disease
- 4. FMO3 and trimethylaminuria Choline bacterial GUT action Trimethylamine (TMA) TMA LIVER FMO3 XFMO3 trimethylaminuria TMA N-oxide
- 5. GENES FMO3 mutations causative of TMAuria or implicated in the disorder T201K M405IfsX R51G N114S A52T I199T R238P E314X E32K M82T P153L W388X G475D R308Q Q470X 532 M66I G148X R223Q I37T M434I R500X V143E D198E E305X V58I K64KfsX2 C197fsX K394KfsX11 R492W R387L N61S
- 6. Amino acids – different ways we name them Full name 3 letter code 1 letter code alanine ala A glycine gly G glutamic acid glu E leucine leu L lysine lys K proline pro P X = STOP
- 7. Primary TMAU –genetic basis Enzyme activity trimethylamine trimethylamine N-oxide P153 L153 Time (min.) P (proline) at position 153 – normal enzyme activity L (leucine) at position 153 – enzyme activity severely reduced Nature Genetics, 1997, 17(4): p. 491-4 Dolphin, Janmohamed, Smith, Shephard, Phillips
- 8. Diagnosis - Urine analysis Measures the concentrations of TMA and TMA N-oxide Results are usually given as a percentage TMA N-oxide X 100 TMA + TMA N-oxide Unaffected = 90 to 100% Mild/moderate’ = 40 to 90 % Severe = less than 40%
- 9. Secondary TMAU • Acquired TMAU – viral hepatitis • Bacterial overgrowth in intestine • Disease states – Liver and kidney • Transient TMAU – Childhood – Menstruation – Precursor overload
- 10. Other factors that increase TMA in urine • Urinary tract infection • Bacterial vaginosis • Cervical cancer • Note for these conditions TMA N-oxide:TMA + TMA N-oxide is normal
- 11. TMAU information links • GeneReview of Trimethylaminuria www.ncbi.nlm.nih.gov/books/NBK1103/ • Clinical Utility Gene Card of Trimethylaminuria www.eurogentest.org Click on trimethylaminuria to download PDF
- 12. DRUGS FM03 – is a drug metabolising enzyme • Drugs (and other chemicals foreign to the body) have to be removed. • Evolved a defence mechanism to clear foreign chemicals from the body – called detoxification. • Foreign chemicals are changed (metabolised) and then leave the body through the urine, bile and/or feces. • Therapeutic drugs are foreign chemicals (as are e.g. cosmetics and many dietary components).
- 13. Detoxification O O drug e.g. N-oxide S-oxide or other foreign FMO3 chemical and TMA Liver
- 14. Pharmacogenetics • How our genes influence the way we handle a drug • Absorption • Distribution • Clearance (e.g. FMO)
- 15. Why drug metabolism and clearance matters Plasma concentration Plasma concentration Metabolism and drug concentration drops before next dose Limited or no metabolism drug concentration does NOT drop before next dose Potential for adverse effect
- 16. Examples of FMO3 drug substrates Drug Class of drug Bupivacaine; Lidocaine Anaesthetics Benzydamine Anti-inflammatory (throat lozenges and sprays) * Chlorpromazine Anti-psychotic Clozapine Anti-psychotic Fluphenazine Anti-psychotic Olanzapine Anti-psychotic Perazine Anti-psychotic (S)-Nicotine Neuronal stimulant Tamoxifen Anti-estrogen * Impaired metabolism in TMAU individuals
- 17. Cytochome P450 monooxygenases CYPs • We have a lot of different CYP genes CYP1 family e.g. CYP1A1, CYP1A2, CYP1B1 CYP2 family e.g. CYP2C19, CYP2D6 CYP3 family e.g. CYP3A4 Many prescription drugs are metabolised by CYP2C19, CYP2D6 and/or CYP3A4
- 18. Drugs are often metabolised by more than one CYP and/or FMO • Each enzyme might produce a different drug metabolite OR • Several enzymes might produce the same metabolite
- 19. Multi-pathway drug metabolism FMOs and CYPs Response to the anti-depressant imipramine CYP1A2 imipramine CYP2D6 desipramine + metabolites FMO1 CYP3A4 imipramine N-oxide
- 20. Drug recycling (retro-reduction) CYP Imipramine Desipramine FMO Several enzymes Imipramine N-oxide
- 21. Multi-pathway Drug metabolism 80% Pathway A Drug 20% Pathway B 10% Drug Pathway A (impaired) 90% Pathway B
- 22. FMO3 genotype and treatment of colon polyps with sulindac E158K E308G 532 Gut bacteria FMO3 sulindac sulindac sulphide sulindac sulphoxide prodrug active drug inactive
- 23. Examples of ‘non-drug’ FMO3 substrates Chemical Type or Origin 4-chlorophenyl methyl Environmental sulfides sulphide ; Diphenyl sulphide Aldicarb; Phorate ; Fenthion pesticides (Phenylselenomethyl)- Fuel additive trimethylsilane Farnesylcysteine modified amino acid Seleno-l-methionine Methionine analogue Numerous metabolites ? Gut bacteria
Editor's Notes
- .
- I